1
|
Creamer A, Fiego AL, Agliano A, Prados-Martin L, Høgset H, Najer A, Richards DA, Wojciechowski JP, Foote JEJ, Kim N, Monahan A, Tang J, Shamsabadi A, Rochet LNC, Thanasi IA, de la Ballina LR, Rapley CL, Turnock S, Love EA, Bugeon L, Dallman MJ, Heeney M, Kramer-Marek G, Chudasama V, Fenaroli F, Stevens MM. Modular Synthesis of Semiconducting Graft Copolymers to Achieve "Clickable" Fluorescent Nanoparticles with Long Circulation and Specific Cancer Targeting. Adv Mater 2023:e2300413. [PMID: 36905683 DOI: 10.1002/adma.202300413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 02/23/2023] [Indexed: 06/18/2023]
Abstract
Semiconducting polymer nanoparticles (SPNs) are explored for applications in cancer theranostics because of their high absorption coefficients, photostability, and biocompatibility. However, SPNs are susceptible to aggregation and protein fouling in physiological conditions, which can be detrimental for in vivo applications. Here, a method for achieving colloidally stable and low-fouling SPNs is described by grafting poly(ethylene glycol) (PEG) onto the backbone of the fluorescent semiconducting polymer, poly(9,9'-dioctylfluorene-5-fluoro-2,1,3-benzothiadiazole), in a simple one-step substitution reaction, postpolymerization. Further, by utilizing azide-functionalized PEG, anti-human epidermal growth factor receptor 2 (HER2) antibodies, antibody fragments, or affibodies are site-specifically "clicked" onto the SPN surface, which allows the functionalized SPNs to specifically target HER2-positive cancer cells. In vivo, the PEGylated SPNs are found to have excellent circulation efficiencies in zebrafish embryos for up to seven days postinjection. SPNs functionalized with affibodies are then shown to be able to target HER2 expressing cancer cells in a zebrafish xenograft model. The covalent PEGylated SPN system described herein shows great potential for cancer theranostics.
Collapse
Affiliation(s)
- Adam Creamer
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Alessandra Lo Fiego
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Alice Agliano
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Lino Prados-Martin
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Håkon Høgset
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Adrian Najer
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Daniel A Richards
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Jonathan P Wojciechowski
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - James E J Foote
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Nayoung Kim
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Amy Monahan
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Jiaqing Tang
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - André Shamsabadi
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Léa N C Rochet
- UCL Department of Chemistry, University College London, London, WC1H 0AJ, UK
| | - Ioanna A Thanasi
- UCL Department of Chemistry, University College London, London, WC1H 0AJ, UK
| | - Laura R de la Ballina
- Department of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, 0372, Norway
- Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 0450, Norway
| | | | - Stephen Turnock
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, SM2 5NG, UK
| | - Elizabeth A Love
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Laurence Bugeon
- Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK
| | - Margaret J Dallman
- Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK
| | - Martin Heeney
- Department of Chemistry, Imperial College London, London, W12 0BZ, UK
| | - Gabriela Kramer-Marek
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, SM2 5NG, UK
| | - Vijay Chudasama
- UCL Department of Chemistry, University College London, London, WC1H 0AJ, UK
| | - Federico Fenaroli
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, 4021, Norway
- Department of Biosciences, University of Oslo, Blindernveien 31, Oslo, 0371, Norway
| | - Molly M Stevens
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| |
Collapse
|
2
|
Bahou C, Szijj PA, Spears RJ, Wall A, Javaid F, Sattikar A, Love EA, Baker JR, Chudasama V. A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability. Bioconjug Chem 2021; 32:672-679. [PMID: 33710874 PMCID: PMC8154211 DOI: 10.1021/acs.bioconjchem.1c00057] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 03/04/2021] [Indexed: 02/08/2023]
Abstract
Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology. Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo. Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents. However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood. Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension. Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue. Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation. Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione. The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide. This platform provides a rare opportunity to combine up to three functionalities on a protein in a site-selective fashion. Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
Collapse
Affiliation(s)
- Calise Bahou
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Peter A. Szijj
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Richard J. Spears
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Archie Wall
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Faiza Javaid
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Afrah Sattikar
- LifeArc,
Accelerator Building, SBC Open Innovation Campus, SG1 2FX, Stevenage, United Kingdom
| | - Elizabeth A. Love
- LifeArc,
Accelerator Building, SBC Open Innovation Campus, SG1 2FX, Stevenage, United Kingdom
| | - James R. Baker
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Vijay Chudasama
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
- Research
Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisbon, Portugal
| |
Collapse
|
3
|
Bahou C, Richards DA, Maruani A, Love EA, Javaid F, Caddick S, Baker JR, Chudasama V. Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones. Org Biomol Chem 2019; 16:1359-1366. [PMID: 29405223 PMCID: PMC6058253 DOI: 10.1039/c7ob03138f] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Herein we report novel protocols for the generation and application of dibromopyridazinediones, an exciting class of disulfide bridging reagents.
Due to their exquisite cysteine-selectivity, excellent stability, and ability to functionally rebridge disulfide bonds, dibromopyridazinediones are emerging as an exciting new class of bioconjugation reagents, particularly in the field of antibody conjugation. Despite this, relatively little work has been performed on the optimisation of their synthesis and subsequent reaction with immunoglobulins. Herein we present a novel synthetic route towards functionalised dibromopyridazinediones, proceeding via an isolatable dibromopyridazinedione-NHS ester. Reaction of this activated intermediate with a variety of amines produces functional dibromopyridazinediones in good to excellent yields. The disulfide rebridging capacity of these reagents was optimised on the clinically relevant IgG1 trastuzumab, resulting in a general method which allows for the generation of site-selectively modified native trastuzumab with over 90% homogeneity (no disulfide scrambling) without the need for protein engineering or enzymatic conjugation.
Collapse
Affiliation(s)
- Calise Bahou
- Department of Chemistry, University College London, London, UK.
| | | | - Antoine Maruani
- Department of Chemistry, University College London, London, UK.
| | - Elizabeth A Love
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK
| | - Faiza Javaid
- Department of Chemistry, University College London, London, UK.
| | - Stephen Caddick
- Department of Chemistry, University College London, London, UK.
| | - James R Baker
- Department of Chemistry, University College London, London, UK.
| | - Vijay Chudasama
- Department of Chemistry, University College London, London, UK. and Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| |
Collapse
|
4
|
Bahou C, Love EA, Leonard S, Spears RJ, Maruani A, Armour K, Baker JR, Chudasama V. Disulfide Modified IgG1: An Investigation of Biophysical Profile and Clinically Relevant Fc Interactions. Bioconjug Chem 2019; 30:1048-1054. [PMID: 30855134 DOI: 10.1021/acs.bioconjchem.9b00174] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Modification of immunoglobulin G (IgG) 1 proteins in cancer treatment is a rapidly growing field of research. Antibody-drug conjugates (ADCs) exploit the targeted nature of this immunotherapy by conjugating highly potent drugs to antibodies, allowing for effective transport of cargo(s) to cancerous cells. Of the many bioconjugation strategies now available for the formation of highly homogeneous ADCs, disulfide modification is considered an effective, low-cost, and widely accepted method for modifying IgG1s for improved clinical benefit. However, little is known about how disulfide modification impacts clinically relevant fragment crystallizable (Fc) region interactions. Although often overlooked as a secondary ADC function, Fc interactions could prove key in the rational design of cancer cell-targeting ADCs through consideration of potent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC). This work explores different IgG1 disulfide modification techniques and the effect they have on quantifiable secondary IgG1 Fc interactions (e.g., CD16a and FcRn). The solvent accessible disulfide residues of trastuzumab, a clinically relevant IgG1, were modified to provide a range of bioconjugates with differing amounts of interchain covalent linkages. It was found that by natively rebridging the IgG1 model, all tested Fc functionalities were not significantly affected. Additionally, in non Fc-specific biophysical experiments (e.g., thermal stability/aggregation), the natively rebridged species provided an exceptional profile, showing no significant change from the tested native antibody. Conjugates with significant disruption of the covalent connectivity of IgG1 chains resulted in a suboptimal Fc profile (CD16a kinetics or ADCC activity), in addition to substandard non Fc-specific attributes (thermal stability). These results advocate native disulfide rebridging as an excellent synthetic strategy for forming homogeneous IgG1 bioconjugates, with no reported negative impact on biophysical profile relative to the native antibody.
Collapse
Affiliation(s)
- Calise Bahou
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom.,LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - Elizabeth A Love
- LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - Siobhán Leonard
- LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - Richard J Spears
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom
| | - Antoine Maruani
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom
| | - Kathryn Armour
- LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - James R Baker
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom
| | - Vijay Chudasama
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom.,Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy , Universidade de Lisboa , 1649-004 Lisbon , Portugal
| |
Collapse
|
5
|
Love EA, Sattikar A, Cook H, Gillen K, Large JM, Patel S, Matthews D, Merritt A. Developing an Antibody-Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein. Chembiochem 2019; 20:754-758. [PMID: 30507063 PMCID: PMC6582441 DOI: 10.1002/cbic.201800623] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Indexed: 01/20/2023]
Abstract
Antibody–drug conjugates (ADCs) are a growing class of therapeutics that harness the specificity of antibodies and the cell‐killing potency of small‐molecule drugs. Beyond cytotoxics, there are few examples of the application of an ADC approach to difficult drug discovery targets. Here, we present the initial development of a non‐internalising ADC, with a view to selectively inhibiting an extracellular protein. Employing the wellinvestigated matrix metalloproteinase‐9 (MMP‐9) as our model, we adapted a broad‐spectrum, nonselective MMP inhibitor for conjugation and linked this to a MMP‐9‐targeting antibody. The resulting ADC fully inhibits MMP‐9, and ELISA results suggest antibody targeting can direct a nonselective inhibitor.
Collapse
Affiliation(s)
- Elizabeth A Love
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Afrah Sattikar
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Hannah Cook
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Kevin Gillen
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Jonathan M Large
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Seema Patel
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - David Matthews
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Andy Merritt
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| |
Collapse
|
6
|
Richardson J, Ruble JC, Love EA, Berritt S. A Method for Identifying and Developing Functional Group Tolerant Catalytic Reactions: Application to the Buchwald–Hartwig Amination. J Org Chem 2017; 82:3741-3750. [DOI: 10.1021/acs.joc.7b00201] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Jeffery Richardson
- Discovery Chemistry
Research and Technologies, Eli Lilly and Company Limited, Erl Wood Manor, Windlesham, Surrey GU20
6PH, United Kingdom
| | - J. Craig Ruble
- Discovery Chemistry
Research and Technologies, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Elizabeth A. Love
- Translational
Research Office Drug Discovery Group, University College London School of Pharmacy, 29−39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Simon Berritt
- Penn/Merck
Laboratory for High-Throughput Experimentation, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States
| |
Collapse
|